Home › Urotheelcelcarcinoom (overgangscelcarcinoom) › Illinois › Chicago
Urotheelcelcarcinoom (overgangscelcarcinoom) klinische studies in Chicago, IL
14 studies voor Urotheelcelcarcinoom (overgangscelcarcinoom) zoeken deelnemers op locaties in en rond Chicago (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruterenFase 1
- Exelixis Clinical Site #26, Chicago
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RekruterenFase 3
- University of Illinois, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruterenFase 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RekruterenObservatieonderzoek
- Northwestern University, Chicago
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
RekruterenFase 1/2
- University of Chicago Medical Center ( Site 1037), Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruterenFase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruterenFase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RekruterenFase 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RekruterenFase 1/2
- The University of Chicago Medical Center - Oncology, Chicago
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
RekruterenFase 2
- Site 02-012 - University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
RekruterenObservatieonderzoek
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RekruterenFase 1
- University of Chicago, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RekruterenFase 2
- Northwestern University, Chicago
Urotheelcelcarcinoom (overgangscelcarcinoom) studies in andere steden
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
- Orange, CA10 studies
Andere studies in Chicago
- Niet-kleincellige longkanker61 studies
- Borstkanker58 studies
- Kanker (alle vormen)51 studies
- Metastatische kanker45 studies
- Prostaatkanker45 studies
- Obesitas41 studies
- Longkanker41 studies
- Eierstokkanker36 studies
- Beroerte34 studies
- Colorectale kanker33 studies
- Hartfalen31 studies
- Overgewicht28 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.